Combining FLASH and spatially fractionated radiation therapy: The best of both worlds.

FLASH therapy Normal tissue toxicity Spatially fractionated radiation therapy

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2022
Historique:
received: 14 04 2022
revised: 23 07 2022
accepted: 03 08 2022
pubmed: 12 8 2022
medline: 21 10 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

FLASH radiotherapy (FLASH-RT) and spatially fractionated radiation therapy (SFRT) are two new therapeutical strategies that use non-standard dose delivery methods to reduce normal tissue toxicity and increase the therapeutic index. Although likely based on different mechanisms, both FLASH-RT and SFRT have shown to elicit radiobiological effects that significantly differ from those induced by conventional radiotherapy. With the therapeutic potential having been established separately for each technique, the combination of FLASH-RT and SFRT could therefore represent a winning alliance. In this review, we discuss the state of the art, advantages and current limitations, potential synergies, and where a combination of these two techniques could be implemented today or in the near future.

Identifiants

pubmed: 35952978
pii: S0167-8140(22)04226-8
doi: 10.1016/j.radonc.2022.08.004
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-177

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Tim Schneider (T)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Cristian Fernandez-Palomo (C)

Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland.

Annaïg Bertho (A)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Jennifer Fazzari (J)

Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland.

Lorea Iturri (L)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Olga A Martin (OA)

Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland; Division of Radiation Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; University of Melbourne, Parkville, VIC 3010, Australia.

Verdiana Trappetti (V)

Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland.

Valentin Djonov (V)

Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland.

Yolanda Prezado (Y)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France. Electronic address: Yolanda.prezado@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH